Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer

被引:99
作者
Horiike, Atsushi
Kimura, Hideharu
Nishio, Kazuto
Ohyanagi, Fumiyoshi
Satoh, Yukitoshi
Okumura, Sakae
Ishikawa, Yuichi
Nakagawa, Ken
Horai, Takeshi
Nishio, Makoto
机构
[1] Canc Inst Hosp, Japanese Fdn Canc Res, Thorac Ctr, Koto Ku, Tokyo 1358550, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Pathol, Koto Ku, Tokyo 1358550, Japan
关键词
epidermal growth factor receptor; epidermal growth factor receptor mutation; epidermal growth factor receptor tyrosine kinase inhibitor; Scorpions Amplified Refractory Mutation System; transbronchial needle aspiration;
D O I
10.1378/chest.06-1673
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Somatic mutations of epidermal growth factor receptor (EGFR) are closely associated with an objective response to EGFR tyrosine kinase inhibitors. However, it is difficult to obtain sufficient tumor samples from patients with non-small cell lung cancer (NSCLC), so these diagnoses are often made using cytology procedures alone. The aim of this study was to detect EGFR mutations in transbronchial needle aspiration (TBNA) samples using both direct sequencing and a highly sensitive assay (Scorpions Amplified Refractory Mutation System; DxS; Manchester, UK) [ARMS], and to compare the sensitivity of these methods. Methods: We enrolled 94 patients (63 men and 31 women),with NSCLC in this study. Cytologic diagnoses were adenocarcinoma (n = 58), squamous cell carcinoma (n = 24), and other types of NSCLC (n = 12). We extracted DNA from the TBNA samples, and EGFR mutations were analyzed using both direct sequencing (exons 19 and 21) and the Scorpions ARMS method (E746 A750del and L858R). Results: Mutations were detected in 31 patients (33%; 14 women and 17 men). Of these, 23 patients had adenocarcinoma, 4 had squamous cell carcinoma, and 4 had other types of NSCLC. Direct sequencing detected 13 mutations (14%) in 13 patients (E746-A750del, n = 6; L858R, n = 7), and the Scorpions ARMS method detected 27 mutations (29%) in 27 patients (E746 A750del, n = 16; L858R, n = 11 patients). Conclusions: Both methods detected EGFR mutations in TBNA samples, but Scorpions ARMS is more sensitive than direct sequencing.
引用
收藏
页码:1628 / 1634
页数:7
相关论文
共 31 条
  • [1] Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay
    Asano, H
    Toyooka, S
    Tokumo, M
    Ichimura, K
    Aoe, K
    Ito, S
    Tsukuda, K
    Ouchida, M
    Aoe, M
    Katayama, H
    Hiraki, A
    Sugi, K
    Kiura, K
    Date, H
    Shimizu, N
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 43 - 48
  • [2] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
    Bell, DW
    Lynch, TJ
    Haserlat, SM
    Harris, PL
    Okimoto, RA
    Brannigan, BW
    Sgroi, DC
    Muir, B
    Riemenschneider, MJ
    Iacona, RB
    Krebs, AD
    Johnson, DH
    Giaccone, G
    Herbst, RS
    Manegold, C
    Fukuoka, M
    Kris, MG
    Baselga, J
    Ochs, JS
    Haber, DA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 8081 - 8092
  • [3] Utility of transbronchial needle aspiration in the diagnosis of endobronchial lesions
    Dasgupta, A
    Jain, P
    Minai, OA
    Sandur, S
    Meli, Y
    Arroliga, AC
    Mehta, AC
    [J]. CHEST, 1999, 115 (05) : 1237 - 1241
  • [4] Epidermal growth factor receptor family in lung cancer and premalignancy
    Franklin, WA
    Veve, R
    Hirsch, FR
    Helfrich, BA
    Bunn, PA
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (01) : 3 - 14
  • [5] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    Fukuoka, M
    Yano, S
    Giaccone, G
    Tamura, T
    Nakagawa, K
    Douillard, JY
    Nishiwaki, Y
    Vansteenkiste, J
    Kudoh, S
    Rischin, D
    Eek, R
    Horai, T
    Noda, K
    Takata, I
    Smit, E
    Averbuch, S
    Macleod, A
    Feyereislova, A
    Dong, RP
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
  • [6] Gasparini S, 1999, Ann Ital Chir, V70, P851
  • [7] Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    Han, SW
    Kim, TY
    Hwang, PG
    Jeong, S
    Kim, J
    Choi, IS
    Oh, DY
    Kim, LH
    Kim, DW
    Chung, DH
    Im, SA
    Kim, YT
    Lee, JS
    Heo, DS
    Bang, YJ
    Kim, NK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2493 - 2501
  • [8] Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
    Hirsch, FR
    Varella-Garcia, M
    McCoy, J
    West, H
    Xavier, AC
    Gumerlock, P
    Bunn, PA
    Franklin, WA
    Crowley, J
    Gandara, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6838 - 6845
  • [9] EGFR mutations in malignant pleural effusion of non-small cell lung cancer:: A case report
    Huang, MJ
    Lim, KH
    Tzen, CY
    Hsu, HS
    Yen, Y
    Huang, BS
    [J]. LUNG CANCER, 2005, 49 (03) : 413 - 415
  • [10] Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
    Kimura, Hideharu
    Kasahara, Kazuo
    Kawaishi, Makoto
    Kunitoh, Hideo
    Tamura, Tomohide
    Holloway, Brian
    Nishio, Kazuto
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3915 - 3921